2cureX AB (publ) (2CUREX.ST)
SEK 0.35
(4.19%)
SEK 0.35
(4.19%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 16.62 Million SEK | -65.12% |
| 2022 | 47.65 Million SEK | -39.8% |
| 2021 | 79.16 Million SEK | 25.56% |
| 2020 | 63.04 Million SEK | 66.6% |
| 2019 | 37.84 Million SEK | 57.5% |
| 2018 | 24.02 Million SEK | 5.17% |
| 2017 | 22.84 Million SEK | 110.72% |
| 2016 | 10.84 Million SEK | -10.15% |
| 2015 | 12.06 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 7.04 Million SEK | -57.6% |
| 2024 Q2 | 7.04 Million SEK | 0.0% |
| 2023 Q1 | 38.58 Million SEK | -19.05% |
| 2023 Q4 | 16.62 Million SEK | -22.61% |
| 2023 FY | 16.62 Million SEK | -65.12% |
| 2023 Q3 | 21.48 Million SEK | -27.82% |
| 2023 Q2 | 29.76 Million SEK | -22.85% |
| 2022 Q3 | 54.27 Million SEK | -13.25% |
| 2022 Q1 | 69.63 Million SEK | -12.04% |
| 2022 FY | 47.65 Million SEK | -39.8% |
| 2022 Q4 | 47.65 Million SEK | -12.19% |
| 2022 Q2 | 62.56 Million SEK | -10.16% |
| 2021 Q2 | 87.27 Million SEK | 43.27% |
| 2021 Q1 | 60.91 Million SEK | -3.37% |
| 2021 Q3 | 81.82 Million SEK | -6.25% |
| 2021 Q4 | 79.16 Million SEK | -3.26% |
| 2021 FY | 79.16 Million SEK | 25.56% |
| 2020 Q1 | 33.51 Million SEK | -11.43% |
| 2020 FY | 63.04 Million SEK | 66.6% |
| 2020 Q2 | 34.43 Million SEK | 2.75% |
| 2020 Q4 | 63.04 Million SEK | -7.2% |
| 2020 Q3 | 67.93 Million SEK | 97.27% |
| 2019 Q1 | 21.36 Million SEK | -11.09% |
| 2019 Q4 | 37.84 Million SEK | -11.36% |
| 2019 Q2 | 38.84 Million SEK | 81.86% |
| 2019 Q3 | 42.69 Million SEK | 9.89% |
| 2019 FY | 37.84 Million SEK | 57.5% |
| 2018 Q3 | 26.45 Million SEK | -13.74% |
| 2018 FY | 24.02 Million SEK | 5.17% |
| 2018 Q4 | 24.02 Million SEK | -9.16% |
| 2018 Q2 | 30.66 Million SEK | -6.69% |
| 2018 Q1 | 32.86 Million SEK | 43.84% |
| 2017 Q3 | 8.18 Million SEK | 0.0% |
| 2017 FY | 22.84 Million SEK | 110.72% |
| 2017 Q1 | - SEK | -100.0% |
| 2017 Q4 | 22.84 Million SEK | 179.0% |
| 2016 FY | 10.84 Million SEK | -10.15% |
| 2016 Q4 | 10.84 Million SEK | 0.0% |
| 2015 FY | 12.06 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 99.125% |
| AcouSort AB (publ) | 34.51 Million SEK | 51.83% |
| Active Biotech AB (publ) | 44 Million SEK | 62.216% |
| Alzinova AB (publ) | 123.18 Million SEK | 86.504% |
| Amniotics AB (publ) | 26.08 Million SEK | 36.268% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -173.572% |
| BioArctic AB (publ) | 1.18 Billion SEK | 98.598% |
| Camurus AB (publ) | 1.9 Billion SEK | 99.129% |
| Cantargia AB (publ) | 223.71 Million SEK | 92.569% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -11.81% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | 44.901% |
| Genovis AB (publ.) | 288.85 Million SEK | 94.245% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | 80.493% |
| Mendus AB (publ) | 755.95 Million SEK | 97.801% |
| Kancera AB (publ) | 65.64 Million SEK | 74.674% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 98.679% |
| LIDDS AB (publ) | 17.65 Million SEK | 5.834% |
| Lipum AB (publ) | 12.11 Million SEK | -37.283% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | 50.524% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 94.036% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | 17.045% |
| NextCell Pharma AB | 81.28 Million SEK | 79.548% |
| OncoZenge AB (publ) | 20.34 Million SEK | 18.265% |
| Saniona AB (publ) | 64.14 Million SEK | 74.081% |
| Simris Alg AB (publ) | 174.55 Million SEK | 90.476% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 96.65% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 97.456% |
| Xintela AB (publ) | 18.39 Million SEK | 9.622% |
| Ziccum AB (publ) | 14.97 Million SEK | -11.041% |
| Isofol Medical AB (publ) | 140.59 Million SEK | 88.175% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 97.828% |
| CombiGene AB (publ) | 120.61 Million SEK | 86.216% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | 92.34% |
| Intervacc AB (publ) | 259.61 Million SEK | 93.596% |
| Alligator Bioscience AB (publ) | 118.45 Million SEK | 85.965% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | 73.348% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | 60.378% |
| Corline Biomedical AB | 100.1 Million SEK | 83.392% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | 90.614% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | 73.251% |
| Aptahem AB (publ) | 63.02 Million SEK | 73.622% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 95.268% |
| Fluicell AB (publ) | 9.34 Million SEK | -77.998% |
| Biovica International AB (publ) | 131.4 Million SEK | 87.349% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | 68.623% |
| Abliva AB (publ) | 87.49 Million SEK | 81.0% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 97.813% |
| I-Tech AB | 152.44 Million SEK | 89.094% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 98.367% |
| Cyxone AB (publ) | 43.65 Million SEK | 61.917% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | 78.873% |
| Biosergen AB | 7.2 Million SEK | -130.871% |
| Nanologica AB (publ) | 77.42 Million SEK | 78.529% |
| SynAct Pharma AB | 228.01 Million SEK | 92.709% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | 37.881% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 98.813% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | 23.397% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 93.026% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -96.629% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | 80.907% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | 41.683% |